Windstar Appoints Paul Barrett as Vice President of Technical Operations

Paul Barrett, Vice President of Technical Operations for Windstar Cruises

We are holding ourselves to a higher standard of operational excellence in everything that we do, which is why we are thrilled to have a consummate professional like Paul join Windstar’s team.

Windstar Cruises announces the appointment of Paul Barrett to Vice President of Technical Operations beginning immediately. Barrett is responsible for the small ship line’s Technical Operations Department overseeing all related aspects with regard to safety and regulatory compliance, inventory control and purchasing, shipyard projects and refits. Barrett also oversees the Engine Department, to ensure timely, diligent and efficient maintenance and safe operation, with a minimum environmental impact as described in the company’s safety management system (SMS), and related policies, procedures, and practices.

“We are continuing to build incredible bench strength of industry leading talent in our efforts to be the world’s best small ship cruise line,” said President John Delaney. “We are holding ourselves to a higher standard of operational excellence in everything that we do, which is why we are thrilled to have a consummate professional like Paul join Windstar’s team.”

Barrett arrives to Windstar with three-plus decades of marine engineering and technical operations experience, having most recently worked for the Holland America Group. Prior to that Barrett was Vice President of Technical Operations at Princess Cruises for seven years having progressed through various management positions and held oversight for the line’s 18 vessels deployed worldwide. Barrett began his maritime career as an Engineer Officer aboard P&O Cruises in 1984.

Barrett completed an Executive Management Leadership Program at the UCLA Anderson School of Management and holds a Master’s degree in Business Administration from California Coast University. Barrett is a Chartered Engineer and Member of the Institute of Marine Engineers, Scientists and Technologists in the U.K. and a member of the U.S.A. Society of Naval Architects and Marine Engineers. A native of England, Barrett resides in Seattle and joins the 130-plus corporate team at Windstar’s headquarters in downtown Seattle.

Windstar operates a fleet of six small cruise ships: three Wind-class sailing ships classified as motor sail yachts (MSY), and three Star-class all-suite ships classified as motor vessels (MV); the ships accommodate 148 to 310 passengers serviced by between 100 and 200 staff and crew depending on the vessel. Barrett leads a team of 128 marine engineers across the fleet.

The industry leader in small ship cruising, Windstar was recently voted #1 Best Boutique Cruise Line by readers of USA Today and was named to Condé Nast Traveler’s 2017 Gold List. The line offers more than 250 cruises annually sailing to 170 ports worldwide with new cruise destinations offered in Arabia in 2017; in Asia and Alaska in 2018; and scheduled to visit a dozen new ports in Europe in 2018.

For additional information on Windstar’s fleet of ships and private yacht-style cruising, contact a travel professional or Windstar Cruises by phone at 877-958-7718, or visit

Share article on social media or email:

Kardiolita Hospital Gets Re-accredited by the JCI Assuring the Highest Quality of Medical Services

Vilnius, Lithuania — (SBWIRE) — 02/20/2017 — JCI – Joint Commission International – accreditation is considered the gold standard in global health care, and JCI accredited hospitals in Europe and worldwide is always the first choice for many International patients seeking medical treatment abroad.

To be accredited by the JCI, a hospital needs to meet a list of criteria, and work by the highest standards and ethics. Kardiolita Hospital in Vilnius, Lithuania, was initially accredited by the JCI in 2013, making the hospital become the part of the elite 800 hospitals worldwide confirmed to provide the highest quality of medical services. However, getting accredited is just the first step – keeping the accreditation is what confirms the hospital keeps on working by the highest standards. Every hospital wanting to keep the accreditation, needs to get reaccredited every 3 years.

In January 2017, Kardiolita Hospital’s processes such as international patient safety goals, patient evaluation and care, anesthesia and surgical care, medication management, prevention and management of infections and many others, were re-evaluated by the team of International experts. After a thorough preparation process, the hospital was confirmed to perfectly meet all the standards and requirements, and was reaccredited by the JCI and given the rights to use the Gold Seal of Approval®.

“Being accredited by the JCI, to us, is a confirmation of our never ending effort to provide the highest quality of services. To our patients, our JCI accreditation is an assurance that when choosing Kardiolita Hospital for their medical treatment abroad, they will get the best possible care, lowest risks and the best service.” – says Andrius Jonutis, the General Deputy Manager at Kardiolita Hospital in Vilnius, Lithuania.

Being recognized as one of the best private general hospitals in Lithuania and the Northern Europe, Kardiolita Hospital offers very competitive prices for medical services, allowing patients to save up to 60% compared to private treatment in the UK, Scandinavian or other European countries.

Visit for more information.

To schedule an appointment or with any questions, send a message to:

Alternatively, please call +44 (0) 203 290 0070 to get all your questions answered.

About Kardiolita Hospital
Kardiolita Hospital is the leading private general hospital in Lithuania, accredited by the JCI and working by the highest industry standards. Established in 1998 Kardiolita Hospital provides full range of medical services – from comprehensive diagnostics to various surgical treatments within many medical areas. Kardiolita Hospital employs 200+ highly qualified Lithuanian doctors with extensive international experience and treatment performance of more than 45+ medical areas. The hospital has long-term experience in treating international patients.

Contact Information:
Contact person: Andrius Jonutis – Deputy CEO
Kardiolita Hospital
Phone: +44 (0) 203 290 0070
Laisves Av. 64a, Vilnius, Lithuania

Samson Resources Appoints Joseph Mills President and CEO

TULSA, Okla., Feb. 20, 2017 /PRNewswire/ — Samson Resources Corporation (“Samson” or the “Company”) today announced that its second-lien creditor group has selected Joseph A. Mills as the Company’s President and Chief Executive Officer, effective as of the date the Company’s global settlement joint plan of reorganization becomes effective. 

Mr. Mills has nearly 35 years of experience in the oil and gas industry, including public company management experience.  Most recently, he served as Chairman of the Board and CEO of Eagle Rock Energy Partners, where he was responsible for creating and managing the strategic direction of the company and its growth as an E&P and Midstream Master Limited Partnership (MLP).   Prior to that role, he founded and served as CEO of Montierra Minerals & Production, L.P., a private equity backed mineral and upstream company.   

Mr. Mills has also served as Senior Vice President of Operations for Black Stone Minerals, L.P., Senior Vice President of El Paso Production Company and Sonat Exploration Company.  Mr. Mills currently serves on the Board of the Houston Producers Forum and is a member of the University of Houston Energy Advisory Board.  Mr. Mills holds a BBA in Petroleum Land Management from the University of Texas, Austin and an MBA in Finance from the University of Houston.

Previously, on February 13, 2017, the Court entered an order confirming Samson’s plan to emerge from Chapter 11 in the near future. This will provide Samson a sustainable capital structure and will position it to compete in the oil and gas industry in the future.

About Samson Resources
Samson Resources is a privately held onshore oil and gas exploration and production company with headquarters in Tulsa, Oklahoma and operations primarily located in East Texas, Louisiana and Wyoming. The Company operates, or has royalty or working interests in, approximately 531,000 net acres of oil and gas properties.

SOURCE Samson Resources Corporation

RYP Announces New Office in Boston’s Financial District and Addition of Senior Tax Counsel

BOSTON, Feb. 20, 2017 /PRNewswire/ — Rath, Young & Pignatelli, P.C. (RYP) is pleased to announce that David S. Davenport, former Deputy Commissioner and Senior Policy Counsel to the Massachusetts Department of Revenue, has joined the Tax Practice Group in Boston.

Mr. Davenport was formerly with the Massachusetts Department of Revenue (DOR) in various roles, including advisor to the Commissioner of Revenue, the Administration, and members of the Legislature with respect to tax policy and technical issues, and he provided policy and technical review and oversight for the Department’s litigation and regulatory functions.  Mr. Davenport also provided advice with respect to the many areas in which state tax laws intersect with federal and international tax laws.  He also served as Acting Deputy Commissioner for the Legislative/External Affairs & Policy Division (LEAP) during 2015-2016, and in that capacity, he provided management oversight for the DOR’s Office of Tax Policy Analysis, Rulings & Regulations Bureau, Office of Legislative Affairs, and Communications group.

To better serve its clients, RYP has also relocated its Boston office to the heart of the Financial District, which is the home to Mr. Davenport. The new office is located at 120 Water Street, Boston, Massachusetts.

The RYP Tax Practice is proud to continue to serve its multistate and multinational business clients throughout New England with their tax matters.  Members of RYP’s state and local tax practice regularly represent multistate clients on state tax matters in New Hampshire, Massachusetts and Vermont.  In addition, RYP’s tax professionals serve on the Board of Trustees for the New England State and Local Tax Forum, a non-profit organization dedicated to excellence in state and local tax policy and education.  RYP is also a sponsor of the Council on State Taxation (COST) in Washington D.C.

Boston Office
120 Water Street, 2nd Fl.
Boston, MA 02109
(617) 523-8080

Concord Office
One Capital Plaza
Concord, NH 03301
(603) 226-2600

The RYP Tax Practice
William F.J. Ardinger
Christopher J. Sullivan
Paul A. Burkett
Kathryn H. Michaelis
David S. Davenport
Olga J. Goldberg
Alex R. Russell

Rath, Young and Pignatelli, P.C. merges traditional legal practice areas with legislative and public policy expertise. We have earned a reputation for achieving client success through skillful and creative advocacy in private party negotiations, before courts, regulatory agencies and legislatures. Our professionals are leaders in key sectors of our economy where business and government intersect including business and finance, energy, tax, health care, environmental and insurance.

Diane J. Vlahos
Rath, Young and Pignatelli, P. C.
Concord, NH 03302-1500
(603) 226-2600

SOURCE Rath, Young & Pignatelli, P.C. (RYP)

Southwest Diagnostic Imaging Selects NextGate to Integrate Patient Data from 33 Free Standing Service Imaging Centers

/ — PASADENA, CA–(Marketwired – February 20, 2017) – NextGate, the leading healthcare technology company for patient and provider identity management, announced today its agreement with Southwest Diagnostic Imaging (SDI) to implement the NextGate Enterprise Master Patient Index (EMPI) to integrate patient data coming from different imaging centers, hospitals, and other healthcare organizations. Probabilistic algorithms in the EMPI will enable data from multiple sources to be matched to the same patient, giving SDI providers a consolidated enterprise view of a patient’s imaging files, streamlined billing processes, and improved patient access. Additionally, the EMPI will assign each patient a global unique patient identifier that serves as a cross-reference for accurate information exchange with external partners such as medical groups and Health Information Exchanges (HIE). This network of integrated information will simplify the process of properly linking a patient’s historic information, thus improving clinical efficiency and enhancing the patient experience by offering all relevant documents at the SDI point of care.

Known as the nation’s largest private practice radiology specialty corporation, SDI is headquartered in Phoenix, Arizona, and is comprised of three radiology practices — Valley Radiologists, Scottsdale Medical Imaging, and EVDI Medical Imaging. These practices serve the Greater Phoenix area through 33 free standing, full service imaging centers and also provide radiology services in several area hospitals for Banner Health, HonorHealth, and Iasis Healthcare.

As part of a new Picture Archiving and Communication System (PACS) deployment and migration to new financial management software, SDI wants to give their providers better visibility into a patient’s care history. This requires the ability to link patient records originating from external partner systems, a standard method of integration, and a reduction in duplicate records which cause gaps in information delivery.

“As an advanced, large medical group, SDI needs a solution that can support data integration from our multiple participating hospitals, radiology practice locations and third party integration points,” said Travis Haskins, Chief Information Officer at SDI. “Based on their proven track record in patient data matching, NextGate is the right partner to bring consistency to our complex patient data via a uniform patient identifier creating a database of information for our care teams to use at the time and place of care.”

NextGate’s EMPI will provide SDI with:

  • A single point for patient identity management across all clinical and financial systems
  • Patient record matching that is accurate, automatic and real-time
  • De-identification processes for reporting and analytics
  • Standard IHE and API services for integration with current and future SDI applications
  • Seamless integration to large medical specialty group EMRs and regional HIEs

The enterprise implementation will allow radiologists, technicians and other staff members to provide improved services to all patients through portals and online billing tools, the ability for remote scheduling, the delivery of electronic reports, and electronic image linking with more ease and security.

About Southwest Diagnostic Imaging

Founded in 2004, Southwest Diagnostic Imaging is a merger between three premier radiology groups in the greater Phoenix metropolitan area. We recognize the value of every life and we are guided by our commitment to medical excellence and leadership. SDI is dedicated to our Arizona communities by providing high quality, safe, value-driven health care to all we serve. Through our affiliates, Scottsdale Medical Imaging, Valley Radiologists, and EVDI Medical Imaging we have provided our patients, community, and medical professionals a tradition of innovation and patient-focused care for over 50 years. Together we are raising the standard of health care. For more information, visit

About NextGate

NextGate helps connect the healthcare ecosystem by accurately identifying and linking patient and provider data from different applications. NextGate’s iDAS (Intelligent Data Aggregation Server) solution framework leverages the company’s industry-leading identity management technology to organize and relate data from enterprise systems to provide a more complete and accurate view of the total healthcare experience. NextGate’s KLAS Category Leader EMPI technology currently manages over 200 million lives and is deployed by the nation’s most successful healthcare systems and health information exchanges. For more information, visit

Aptus Health’s RxStart(TM) Solution Launches with Electronic Health Record Partners to Engage Providers and Patients at the Point of Care

/ — READING, MA–(Marketwired – February 20, 2017) – Aptus Health announces that its RxStart solution, a free sample medication and patient support program, has successfully launched with three Electronic Health Record (EHR) and ePrescribing partners — NextGen Healthcare, Office Ally, and NewCrop — and is now enrolling patients. This milestone illustrates strong market interest and adoption of a new solution that offers a quick, convenient way for healthcare providers to introduce eligible patients to recommended treatments, while encouraging them to follow their medication regimen as directed.

The RxStart solution is built right into the provider’s e-prescribing workflow, allowing them to enroll eligible patients in the program and to facilitate delivery of a free trial medication supply directly to the patient’s home. Patients typically receive their free trial supply within 24 hours, along with educational materials and ongoing telephonic patient support. The overall solution is designed to create a more positive experience for new-to-brand patients — helping close gaps in the desired treatment plan between provider and patient.

Partnering with Electronic Health Record vendors offers point-of-care access for providers

Recent data from Decisions Resources Group shows that providers are looking for more value from their EHRs; 40% say they want to see patient assistance programs and one-third of them want to see coupons, vouchers, and/or drug samples in the EHR. Aptus Health’s RxStart solution addresses these needs by embedding prescription and patient support tools within the EHRs of its strategic partners.

“We are pleased to be partnering with these forward-thinking EHR and ePrescription companies. Each of these partners realized early on the benefit of offering free medication trial, home delivery, and personalized patient support as part of the provider’s daily workflow,” said Robert MacMillan, Vice President, EHR and Innovation at Aptus Health. “Now, with these partnerships and integrations in place, together we are extending access to the RxStart solution to approximately 75,000 U.S. providers and their patients.”

For EHR and ePrescribing partners, the RxStart solution is one more way to offer health care solutions to their users. “The RxStart solution is unique in its ability to leverage the power of the EHR workflow to educate, inform, and enroll patients into a program that provides free trial medication for which they are eligible,” said Gene DuAime, VP Life Science & Strategic Alliances of NextGen Healthcare. “It also reflects our continued mission to make our EHR an indispensable tool for ambulatory practitioners.”

“Medical practices today are faced with greater demands to operate more proficiently and to blend quality patient care with strong customer service and an efficient back-room operation,” said Brian O’Neill, president and CEO of Office Ally. “Partnering with Aptus Health to bring our user base this innovative RxStart solution is just one more way we’re helping providers smartly use technology to make their office more efficient while making their lives easier and better serving their patients.”

“We are hearing from our doctors that the RxStart solution is improving their patients’ new medication experience,” said Lawrence Susnow, M.D. Chief Medical Officer at NewCrop. “Our providers appreciate the easy and comprehensive nature of the program, integrated into the prescribing workflow. The program directly addresses compliance issues with the initial free trial, home delivery, and the support of a personalized care plan.”

For more information about joining Aptus Health as a strategic partner, contact

About Aptus Health

Aptus Health offers health and life sciences companies a truly connected approach to engaging healthcare professionals, consumers and other stakeholders through an array of high-value digital information channels and services. By applying this portfolio of assets — informed by rich engagement data and analytics — Aptus designs and builds integrated multichannel engagement solutions that allow its clients to connect with their customers at key points in their decision-making journeys and impact behavior at scale.

Aptus Health is a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) (“Merck”), with its own independent employees, editorial process, business and financial operations, and governance. Aptus Health maintains its information independent from Merck and maintains confidentiality of its customers’ information from Merck. More information can be found at

About NextGen Healthcare

NextGen Healthcare, a wholly owned subsidiary of Quality Systems, Inc., helps ambulatory care organizations succeed in value-based care by empowering them to nurture measurably healthier patients and communities at a lower cost. It does this with deep clinical, financial, operational, and regulatory expertise, using consulting and educational services coupled with a robust technology portfolio of flexible, scalable, and cost-effective ambulatory solutions; including a certified EHR, practice management, interoperability, care management, patient engagement and population health management, analytics, e-transaction, and revenue cycle management solutions. For more information, visit Follow NextGen Healthcare on Twitter, Facebook, or LinkedIn.

About Office Ally

Office Ally has been supporting practices with innovative, practical products since its founding in 2000. In 2015 Office Ally experienced another record-setting year, adding 40,000 clients to a total of 330,000 providers now using one or more products provided by Office Ally. All of Office Ally’s products and services are offered at minimal or no cost to providers and are backed by one of healthcare’s largest customer and technical support centers available 24/7. Office Ally’s complete suite of interactive ASP Internet-based solutions includes a patient health registry — Patient Ally™, electronic health records — EHR 24/7™, practice management — Practice Mate™, clearinghouse, OA-Rx e-prescribing and Intake Pro™. Further information may be obtained at

About NewCrop

NewCrop is a leading electronic prescribing service and has been deployed in a wide range of EHRs and medical networks since 2003. The company’s user interface allows for rapid installation of fully expedited e-Prescription networking, as well as Meaningful Use certifications, lab integration, secure messaging, registry reporting, DEA-compliant EPCS audit, and more. All services are available as an integrated user interface and/or data services for all individual features, facilitating easy and flexible installations to fast track network and Meaningful Use certifications. Please visit or contact for more information.

About Merck

For over a century, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit and connect with us on Twitter, Facebook, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (

Guy & O’Neill, Inc. Wins 2017 Grocery Headquarters Trailblazer Award

FREDONIA, Wis., Feb. 20, 2017 /PRNewswire/ — Guy & O’Neill, Inc., a private label and contract manufacturer, is pleased to announce that they were awarded the 2017 Private Label Trailblazer Award by Grocery Headquarters in their February, 2017 issue. The award is given out annually to those companies recognized for driving growth in the private label industry. 

Guy & O’Neill was recognized for its innovation in the personal lubricant category.  The company recently launched a new line of personal lubricants that is made from all natural ingredients and is preservative, paraben and sugar free. “We are very pleased to receive the award. The Trailblazer Award recognizes Guy & O’Neill’s commitment to delivering innovation that meets unmet consumer needs and that helps retailers grow their private brands,” stated Greg Fries, Guy & O’Neill’s Vice President of Marketing. “Consumers are increasingly looking for personal care products with fewer, more natural ingredients. Our personal lubricant was the first to have the claim Made with All Natural Ingredients approved by the FDA. I could not be more proud of the team,” he added.

The full article can be found here,

About Guy & O’Neill
Guy & O’Neill, Inc. was founded in 1975 with headquarters in Fredonia, Wisconsin. It is focused on contract, private label and consumer goods manufacturing for wet wipes, personal care, beauty care, household care, adult care and automotive care. Guy & O’ Neill has created and delivered innovation for Fortune 500 retailers and consumer product companies with an emphasis on the highest standards for business ethics, quality and customer service.  For more information visit


SOURCE Guy & O’Neill, Inc.

Sub-Sahara Africa – Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan


There has been a paradigm shift in the burden of illness and non-communicable diseases (NCDs) across sub-Saharan Africa, which in turn is driving the demand for chronic prescription drugs. The growing incidence of more Western lifestyle diseases such as cardiovascular disease (CVD), cancer, diabetes and respiratory disease, in addition to infectious and parasitic illness, will present the pharmaceutical industry in Africa with a business opportunity of $40.8 billion in 2019.

“An increase in health spending will encourage local manufacture of drugs,” said Transformational Health Research Analyst Saravanan Thangaraj. “We expect this increase in local formulation and filling to be protected by regulatory and tariff barriers, so international players will be looking for local contract manufacturers and other strategic partnerships.”

African Pharmaceuticals Market, Forecast to 2020, part of Frost & Sullivan’s Life Sciences Growth Partnership Service program, provides valuable insights for Big Pharma and generic manufacturers looking to set up manufacturing units in Africa; as well as over-the-counter (OTC) and chronic disease therapeutics manufacturers; large, local enterprises in Kenya and Nigeria; and Tier 1 distributors. In addition to a brief competitive overview, the research details the pricing and regulatory environment, revenues and growth forecasts, as well as market dynamics particularly challenges, drivers and restraints. Therapeutic areas covered include haematology, oncology, men’s health, central nervous system (CNS), women’s health, diabetes, cardiovascular, dermatologicals, gastrointestinals, cough and colds, nutritionals, analgesics and anti-infectives.

Heavy dependence on price, coupled with complexities associated with public sector tendering, make it difficult for multinationals to compete in this space. The private market, on the other hand, faces challenges with regards to fragmented payer channels between donors, private insurance payers and employers, even as high out-of-pocket expenses restrict patient access to medicines.

Nonetheless, several trends are encouraging investment:

• The regulatory environment for manufacturing in East Africa is improving rapidly with increasing regional harmonisation;
• Pharmaceutical spending in Africa was noted to be growing by 10.6 percent;
• Out-of-pocket spend on healthcare is increasing;
• The share of OTC drugs is high, indicative of a culture of self-medication in Nigeria and Kenya;
• Contribution of NCDs to the healthcare burden in Africa will rise by 21 percent through 2030.

“Addressing loopholes in the supply chain and distribution channels is crucial for foreign companies to ensure product availability and prevent circulation of counterfeit drugs,” added Thangaraj. “Investing in technical training of distributors and pharmacists, and product-specific initiatives like barcodes and holograms to track counterfeits, can also help minimize drug trafficking and enhance the brand’s image.”

About Frost & Sullivan

Frost & Sullivan (, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

African Pharmaceuticals Market, Forecast to 2020 / MC24-52

Rapier Gold Inc. Announces Private Placement to Continue Exploration Programs at Pen Gold Project

VANCOUVER, BRITISH COLUMBIA–(Marketwired – Feb. 20, 2017) –


Rapier Gold Inc. (TSX VENTURE:RPR) (the “Company”) is pleased to announce a non-brokered private placement of non-flow through units (the “NFT Units”) and flow through units (the “FT Units”) on a best efforts basis at a price of $0.10 per Non-Flow Through Unit (the “NFT Units”) and $0.115 per Flow Through Unit (the “FT Units”) for aggregate proceeds of up to $2,500,000 (the “Offering”).

Each of the NFT units and FT Units will include a transferable common share purchase warrant that will entitle the holder to purchase one common share at an exercise price of $0.15 for a period of 24 months. The Company reserves the right to increase the size of the private placement or to modify the type, nature and/or price of the units for any reason. The Offering and any modification to it are subject to compliance with applicable securities laws and approval of the TSX Venture Exchange. The Company may pay finders’ fees in accordance with the policies of the TSX Venture Exchange. The shares will be subject to a statutory four-month hold period. Secutor Capital Management Corp., as well as other parties, are acting as finders on this financing.

The proceeds from the issuance of the FT Units will be used to incur Canadian Exploration Expenses on the Issuer’s Pen Gold Project located in the Province of Ontario, and the proceeds from the NFT Units will be used by the issuer for general working capital.

The results of the Company’s summer exploration program and winter drilling program were summarized in detail in the Company’s news release dated December 6, 2016.

Diamond drilling work permits are in place and Rapier has finalized a winter drill program of approx. 3,000 m in three areas of the Pen Gold Project;

  • Area 1 – Nib Yellowknife Area – exploration extensions of anomalous values and determine what the width and possible strike length are, once attitude of mineralization is determined. 3-4 holes
  • Area 2- Broadsword Area – Determine if grade and thickness warrant further work. 2-3 holes
  • Area 3 – Talc Mine Area – 5-7 holes to explore extension of New Vein Zone from hole PG13-108
  • Follow up for Areas 1 – 3. 10 holes; these will be allocated depending on results from the previous drilling. Targets along the Eastgate-Westgate and Porphyry trends will be investigated during the program and drill holes diverted there if warranted. The three areas are shown in Appendix 1.

High resolution aero magnetics will be flown in late winter to early spring over the Pen Gold South and newly staked grounds, totally over 12,000 hectares, to complete the geophysics coverage and to aid in geological interpretation and exploration targeting for the 2017 summer field season.

Speaking of the financing, Roger Walsh, the Company’s President, stated, “The Company’s exploration strategy has been in process since early last year where the summer exploration program, designed to deliver high value drill targets, would be funded by capital raising in late 2016. This is consistent with the corporate presentations and information provided to the market and shareholders. There has been a significant delay in raising this funding which is directly attributable to the Company providing exclusivity to a company that presented a business transaction. In compliance with the conditions of that exclusivity, the Company refrained from raising funds while the Special Committee evaluated a proposal for a potential business transaction.” See news release of February 15, 2017.

Certain directors and officers of the Company may acquire securities under the private placement. Such participation is considered to be a “related party transaction” as defined under Multilateral Instrument 61-101 (“MI 61-101”). The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to or the consideration paid by such persons will exceed 25% of the Company’s market capitalization.

Gary Wong, P. Eng., Vice-President Exploration of the Company, and a Qualified Person under the definition in National Instrument 43-101, has reviewed and approved the technical content of this release.

Pen Gold Project Summary

  • The Company’s activities are exclusively focused on exploring the Pen Gold Project, comprising approximately 19,333 hectares (approximately 193 sq. km.) located on Highway 101, 75 km south west of Timmins, Ontario. (See Appendix 2). The project is approximately 45 km southwest of Tahoe Resources Timmins West Mine and the recently discovered 144 Exploration Area.
  • The Pen Gold Project is located approximately 85 km northeast of Goldcorp’s Borden Gold Project. In March 2015 Goldcorp acquired this project in the takeover of Probe Mines for $526 million. Goldcorp are actively advancing the Borden Gold Project as a source of ore for the 11,000 tpd Dome Mill, located 160 km away in Timmins.
  • The Pen Gold Project appears to be on the western extension of the Porcupine-Destor Fault Zone (PDFZ), one of the most productive gold structures in the world. This fault zone extends east into Quebec and hosts many of the largest and most famous gold mines in Canada. The Timmins Camp has produced approximately 72.5 million ounces of gold to date.
  • Probe Metals acquired the Ivanhoe Project located to the west of Rapier’s Pen Gold Project and the West Porcupine and Ross Properties to the east of the Pen Gold Project.


Roger Walsh, President & CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or the securities laws of any state of the United States and may not be offered or sold within the United States or to, or for the account or the benefit of, any person in the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

Cautionary Note Regarding Forward Looking Statements: Certain disclosure in this release constitutes forward-looking statements. In making the forward-looking statements in this release, the Company has applied certain factors and assumptions that are based on the Company’s current beliefs as well as assumptions made by and information currently available to the Company, including that the Company is able to procure personnel, equipment and supplies required for its exploration activities in sufficient quantities and on a timely basis and that actual results of exploration activities are consistent with management’s expectations. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors include, among others, that actual results of the Company’s exploration activities will be different than those expected by management and that the Company will be unable to obtain financing, or will experience delays in obtaining any required government approvals or be unable to procure required equipment and supplies in sufficient quantities and on a timely basis. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

To view Appendix 1, please visit the following link:

To view Appendix 2, please visit the following link:

Satyam Shivam Sundaram Meditation School Announces Tibetan Singing Bowls – Sound Healing Teacher Training Course in Rishikesh & Goa, India

Rishikesh, Uttarakhand — (SBWIRE) — 02/20/2017 — The Satyam Shivam Sundaram Meditation School will be providing a Sound Healing Course in Rishkesh and Goa, India that will last for 3 days or 30 hours. This sound healing teacher training and certification course will be held under the guidance of Shiva Girish, a modern age Tantra Yoga Meditation master who has taught 10000 students countries for the last 7 years. People from every field are welcome to join this unique and special course which infuses Indian and Tibetan healing techniques together to create peace and harmony among the minds and lives of people through the power of sound and vibrations.

This Tibetan Singing Bowls sound healing teacher training program has been designed in a way that during those 30 hours, you will not only learn how to use the Tibetan singing bowls but also learn and understand how various sounds and vibrations can be used to heal a person’s mind and body internally without the usage of any medicines and surgery. You will lean and practice with masters and students who have the desire to create a sustainable healing method which would suit everyone, regardless of their beliefs and backgrounds. By the end of the course, you will be able to conduct your own 1 or 2-day group sound healing workshops and be able to provide private sound healing sessions.

The Tibetan Singing Bowls – Sound Healing Therapy Teacher Training at Satyam Shivam Sundaram Meditation School teaches you how to use Tibetan Sound Bowls Therapy & Sacred Mantra Meditation techniques to create a therapeutic benefit at physical, mental, emotional, energetic and spiritual level. It is a great opportunity of music lovers, alternative healers, tarot card readers, yoga and meditation masters and practitioners, Reiki healers and other holistic health practitioners to learn a scientifically-proven technique which would enhance your healing practices and add a new tool to help you with your journey towards spirituality and healthy living.

The main and objective of this Tibetan Singing Bowl Sound Healing Teacher Training at Satyam Shivam Sundaram Meditation School is to learn and understand the core principles of Sound healing and meditation and to apply this knowledge to help others in dealing with their mental, physical and emotional stress by conducting workshops and offering private sessions while making it a fulltime profession for yourself. This teacher training is suitable for those who are in 18-65 age group. No prior experience in the field of meditation or sound healing is required as the course covers all the basic fundamentals of sound healing therapy, thus providing an overall coverage of every technique and usage of sound and vibrations.

What is included in the Tibetan Singing Bowls Therapy – Sound Healing Teacher Training Program is the accommodation for 3 nights with Private Room with Double Bed and attached bathroom with hot and cold shower and 24×7 room service facilities. Students will also receive everyday healthy breakfast & lunch, and a sound healing training manual which would allow them to continue their practice after the course is over.

Here is Blog link from past sound healing trainings:

Facebook Page:

About Satyam Shivam Sundaram Meditation Schools
Satyam Shivam Sundaram Meditation Schools is a Spiritual Transformation Retreats centre which offers Chakra Energy Healing therapy, Active Dynamic Meditation Teacher Training certification in Located in Rishikesh, Uttarakhand – India, here is info about Upcoming Dates For Tibetan Singing Bowls – Sound Healing Therapy Teacher Training in Rishikesh, Goa India.

Contact: Satyam Shivam
Company: Satyam Shivam Sundaram Meditation Centre
Address: Hotel Brijwasi Palace, Second Floor, Behind Parmarth Niketan, Ram Jhula, Rishikesh, Uttarakhand 249304 INDIA
Contact: +917888206883
Email: –